Antiviral therapy for hepatitis B virus during second pregnancies
Antiviral therapy for hepatitis B virus during second pregnancies
复制标题
第二次妊娠期间乙型肝炎病毒的抗病毒治疗
DOI：
10.1111/jog.13540
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Saitoh S.
中科院分区：
文献类型：
--
作者：
Wakano Y;Sugiura T;Endo T;Ito K;Suzuki M;Tajiri H;Tanaka Y;Saitoh S.
B型肝炎病毒（HBV）的母婴传播是受感染母亲的一个主要问题，特别是在她们的第一个孩子尽管进行了免疫预防但仍成为HBV携带者之后。八位母亲的第一个孩子已经成为HBV携带者，尽管免疫预防，在随后的怀孕期间进行抗病毒治疗。所有孕妇血清均阳性的B型肝炎表面抗原和B型肝炎e抗原。在治疗组（3名接受拉米夫定，2名接受替诺福韦）中，所有婴儿（5/5）的HBV母婴传播都得到了成功预防。另一方面，未经治疗的婴儿中有三分之二成为HBV携带者。对母亲或婴儿均无显著不良影响。在第二次妊娠期间使用拉米夫定和替诺福韦的抗病毒治疗成功地预防了高危母亲的HBV母婴传播。
Mother‐to‐child transmission of the hepatitis B virus (HBV) is a major concern for infected mothers, especially after their first child has become an HBV carrier despite immunoprophylaxis. Eight mothers whose first child had become an HBV carrier despite immunoprophylaxis were referred for antiviral therapy during the subsequent pregnancy. All pregnant women were seropositive for both the hepatitis B surface antigen and hepatitis B e antigen. In the treatment group (three receiving lamivudine and two receiving tenofovir), mother‐to‐child transmission of the HBV was successfully prevented in all infants (5/5). On the other hand, two of three infants became HBV carriers in the untreated group. There were no significant adverse effects in either mothers or infants. Antiviral therapy using lamivudine and tenofovir during the second pregnancy successfully prevented mother‐to‐child transmission of the HBV for high‐risk mothers.